Lyophilized human platelet lysate: manufacturing, quality control, and application
We successfully developed a method to produce well-applicable L-HPL. The comparison of L-HPL with HPL did not reveal any relevant differences regarding quality control parameters of routine testing, growth factor concentrations and hMSC functionality, demonstrating the suitability of L-HPL as a cell culture supplement. These results emphasize the potential of L-HPL as a sustainable and ethical alternative to animal-derived serum products in biomedical research and drug development.
Authors
- Konstanze Aurich (ORCID: https://orcid.org/0000-0003-3365-0168)
- Janosch Schoon (ORCID: https://orcid.org/0000-0003-2337-0795)
- Sander Bekeschus (ORCID: https://orcid.org/0000-0002-8773-8862)
- Debora Singer (ORCID: https://orcid.org/0000-0003-2335-1607)
- Jan Wesche (ORCID: https://orcid.org/0000-0001-5025-7355)
- A Dahms
- Dirk Stobbe
- Kerstin Wendland
- Lea Koblin
Institutions
- Universitätsmedizin Greifswald (DE)
- Leibniz Institute for Plasma Science and Technology (DE)
- University of Rostock (DE)
Publication Details
- Journal
- Frontiers in Cell and Developmental Biology
- Published
- 2025-01-27
- DOI
- https://doi.org/10.3389/fcell.2025.1513444
- Citations
- 3
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 4.88
Funders
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Universität Greifswald